JPRN-UMIN000019879已完成2 期
A phase II clinical trial of personalized peptide vaccination in combination with metformin for castration-resistant prostate cancer (CRPC) - Personalized peptide vaccination with metformin for CRPC
Cancer Vaccine Center, Kurume University School of medicine0 个研究点目标入组 35 人开始时间: 2015年11月24日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •The following patients must be excluded: 1) Patients with severe symptoms (active and severe infectious disease, circulatory disease, respiratory disease, kidney disease, immunodeficiency, disturbance of coagulation). 2)Active double cancer (synchronous double cancer and metachronous double cancer within 5 disease-free years), excluding carcinoma in situ (lesions equal to intraepithelial or intramucosal cancer) judged to have been cured with local treatment. 3) Patients with the past history of severe allergic reactions. 4) Patients who do not accept contraception from the 1st vaccination until 70 days after the last vaccination. 5) Patients who are judged inappropriate for entry to this clinical trial by doctors.
研究者
相似试验
已完成
2 期
A phase 2 clinical trial of personalized peptide vaccination for castration-resistant prostate cancer (CRPC) patients with slight bone marrow suppressioJPRN-UMIN000019802Cancer Vaccine Center, Kurume University School of medicine35
已完成
2 期
A randomised phase II trial of personalized peptide vaccination plus "Keppuchikuoto" vs personalized peptide vaccination alone for non small cell lung cancer patientsnresectable non smaii cell lung cancerJPRN-UMIN000015173Kurume Unversity Cancer Vaccine Center60
已完成
2 期
Phase II Clinical trial of personalized peptide vaccine for cancer patients - Effect of extended dose interval on the immun inductionmalignant tumorJPRN-UMIN000006927Kurume University Cancer Vaccine Center60
已完成
2 期
Phase II Clinical trial of personalized peptide vaccine for cancer patientsmalignant tumorJPRN-UMIN000001482Kurume University Cancer Vaccine Center150
已完成
2 期
Phase II Clinical trial of personalized peptide vaccine for patients with maligant tumors (gastrointestinal cancers, hepato-biliary-pancreatic cancers, thoracic malignant tumors, non-epithelial malignant tumors, genitourinary cancers, gynecological cancers, breast cancers, and rare cancers) - Effect of extended interval dosing on immune responsesmalignant tumorJPRN-UMIN000011230Kurume University CanCER Vaccine Center800